Sabby Management’s Zevra Therapeutics ZVRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$635K Buy
+57,850
New +$686K 7.04% 5
2023
Q1
– Sell
-70,000
Closed -$321K – 125
2022
Q4
$321K Sell
70,000
-178,592
-72% -$907K 0.28% 33
2022
Q3
$1.55M Sell
248,592
-45,895
-16% -$260K 1.96% 12
2022
Q2
$1.31M Buy
294,487
+35,707
+14% +$163K 0.89% 19
2022
Q1
$1.3M Buy
258,780
+238,780
+1,194% +$1.52M 0.19% 35
2021
Q4
$174K Sell
20,000
-21,531
-52% -$192K 0.03% 141
2021
Q3
$387K Sell
41,531
-130,632
-76% -$1.32M 0.05% 123
2021
Q2
$2.21M Buy
+172,163
New +$1.85M 0.31% 52

Other funds holding ZVRA

Sabby Management's ZVRA Position: Q3 2026 in Review

Sabby Management opened a new position in Zevra Therapeutics (ZVRA) in Q3 2026: 57,850 shares worth $635K. The stake represents 7.04% of the portfolio and ranks #5 among its holdings. This is a return to the name: Sabby Management previously reported a position in ZVRA as recently as Q4 2022.

Sabby Management first reported a position in ZVRA in Q2 2021 and has held it in 8 quarters since. The position peaked at $2.21M in Q2 2021. 174 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

  • Sabby Management held 57,850 shares of Zevra Therapeutics worth $635K as of Q3 2026.
  • Zevra Therapeutics was a new Sabby Management position in Q3 2026.
  • Zevra Therapeutics made up 7.04% of Sabby Management's portfolio in Q3 2026, its #5 holding.
  • Sabby Management first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • Sabby Management's Zevra Therapeutics position peaked at $2.21M in Q2 2021.
  • 174 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on Sabby Management's 13F filing for Q3 2026, filed 13 Nov 2026.